What Is Meigs Syndrome?

First described in 1937 by the American gynecologist Joe Vincent Meigs, this rare, benign triad links an ovarian fibroma, a solid, non-cancerous tumor, to both abdominal fluid (ascites) and a pleural effusion that vanish entirely once the tumor is surgically removed. The condition was first described in 1937 by American gynecologist Joe Vincent Meigs at Massachusetts General Hospital, and its hallmark triad still guides diagnosis today.

Because initial imaging and blood tests often resemble advanced ovarian cancer, the path to confirmation can feel alarming.

This detailed guide walks through every layer of Meigs syndrome, from its 1937 origins and classic triad to imaging pitfalls, the pseudo-Meigs distinction, and the surgical resolution that usually clears both effusions for good.

Defining Meigs Syndrome and Its Classic Triad

Buried in a small but clinically important corner of gynecology sits a triad first formalized by Joe Vincent Meigs nearly a century ago. A benign ovarian fibroma, often discovered in postmenopausal women, generates enough fluid accumulation to mimic metastatic disease. Recognizing that mimicry early is the whole reason the syndrome matters to your workup.

The Three Hallmark Features Working in Concert

Three findings must appear together. First, a benign ovarian fibroma sits on or near the ovary, usually as a solid, well-defined mass. Second, ascites fills the peritoneal cavity, sometimes enough to distend the abdomen and trigger shortness of breath. Third, a pleural effusion pools in the chest cavity, most often on the right side. Remove the fibroma surgically, and both fluid collections resolve on their own within weeks.

Why the Triad Drives Clinical Recognition

Each piece of the triad on its own could mean almost anything; together they form a near-unique fingerprint. Ovarian fibromas account for roughly 1–5% of all ovarian neoplasms, and only a fraction of those generate enough ascites and pleural fluid to mimic cancer. Spotting the triad early shortens the path to a correct diagnosis, reduces invasive testing, and points the care team straight toward curative surgery instead of palliative cancer staging.

How Ascites and Pleural Effusion Develop

The fluid does not appear by accident. Researchers have proposed several mechanisms, and most modern explanations blend lymphatic compression with inflammatory signaling.

Lymphatic Obstruction and Inflammatory Mediators

The leading theory points to obstructed pelvic lymphatics: as the fibroma enlarges, it blocks the small vessels that normally return interstitial fluid to the bloodstream, and fluid leaks into the peritoneal cavity. A secondary pathway involves inflammatory mediators released by the tumor, including vascular endothelial growth factor (VEGF), which increases vascular permeability and pushes more fluid out of capillaries. The result is ascites that can reach several liters in volume.

Right-Sided Predominance and Diaphragmic Migration

About 70% of pleural effusions in Meigs syndrome appear on the right side. The most accepted explanation is that ascitic fluid tracks up through tiny defects in the diaphragm’s lymphatic network and pools preferentially in the right pleural space, where diaphragmatic lymphatics drain. Larger tumors and higher VEGF levels tend to produce larger effusions, though the exact relationship varies between patients.

“Tip: when a right-sided pleural effusion appears alongside a pelvic mass and ascites, raise Meigs syndrome as a possibility before assuming metastatic ovarian cancer.

Pseudo-Meigs Syndrome and the Ovarian Cancer Question

The diagnostic alarm usually comes from one source: a CA-125 blood test that returns elevated, sometimes dramatically. CA-125 is a tumor marker widely used to track epithelial ovarian cancer, and it rises in many benign conditions too, including Meigs syndrome. That overlap is what makes the condition a known mimicker.

How Pseudo-Meigs Differs From the Classic Triad

Pseudo-it applies whenever the ovarian tumor is not a fibroma but still produces the same fluid pattern. Thecomas, mature teratomas, leiomyomas (uterine fibroids extending to the ovary), Brenner tumors, and granulosa cell tumors have all been reported. The label matters less than the principle: any ovarian mass with ascites and pleural effusion needs histopathology to settle the question.

Why Histopathology Is Non-Negotiable

Imaging alone cannot distinguish a fibroma from a borderline tumor or early carcinoma. CA-125 values overlap heavily between benign and malignant causes, especially in postmenopausal women. Only surgical removal and microscopic examination of the specimen can confirm a benign fibroma. Until that step is complete, the care team treats the case as potentially malignant, which is exactly why the syndrome triggers so much pre-operative anxiety.

Diagnostic Workup From Imaging to Histology

The workup moves from broad to specific, narrowing the possibilities with each step.

First-Line Imaging and Effusion Analysis

• ▸Pelvic ultrasound: the first tool, used to characterize the mass as solid and well-defined, which raises suspicion for fibroma.
• ▸CT or MRI of abdomen and pelvis: maps the tumor’s size, looks for peritoneal implants, and quantifies ascites.
• ▸Chest imaging: confirms and measures the pleural effusion, often right-sided.
• ▸Thoracentesis and paracentesis: sample the effusions; in it the fluid is typically a transudate, which helps rule out infection or malignant pleural disease.

Laboratory Markers and Surgical Confirmation

CA-125 provides a number, not a verdict. Elevated values, sometimes in the hundreds or thousands, overlap too broadly to be diagnostic on their own. The decisive step is surgical exploration, often laparoscopic, with intraoperative frozen section to confirm a benign fibroma before the procedure ends. Final histopathology on the resected specimen closes the loop, and until that report returns, the team plans for cancer; once it returns, the plan pivots to recovery and surveillance.

Surgical Treatment and Resolution of Fluid Accumulation

The operation is curative. Once the fibroma is out, ascites and pleural effusion begin to clear within days and resolve completely within a few weeks in most patients.

Resection Approaches and Fertility Considerations

For postmenopausal women, the standard is total hysterectomy with bilateral salpingo-oophorectomy, removing the uterus and both ovaries. For younger patients with a unilateral fibroma and a strong desire to preserve fertility, unilateral oophorectomy can be curative and leaves reproductive function intact. Both laparotomy and minimally invasive laparoscopic approaches have been used successfully, and the choice depends on tumor size, surgical history, and surgeon preference.

Expected Timeline for Fluid Resolution

Most patients see ascites resolve within two to four weeks after surgery. The pleural effusion typically clears on a similar timeline, confirmed by follow-up chest imaging at four to six weeks. Recurrent fluid accumulation after a confirmed fibroma resection is rare and should prompt a fresh evaluation rather than reassurance.

Prognosis, Recurrence Risk, and Long-Term Outlook

The long-term outlook is the best part of this story. Once the fibroma is removed, the condition does not recur, and there is no malignant potential to monitor.

Excellent Prognosis After Complete Resection

Patients return to baseline health without ongoing cancer surveillance, repeat imaging, or long-term medication. Recurrence of the triad after a confirmed benign fibroma is uncommon, and any new fluid accumulation should trigger a fresh workup rather than an assumption that the original syndrome has returned. Fertility-sparing surgery preserves normal reproductive function in young women, and pregnancy after the procedure is well documented.

What to Discuss With Your Care Team

• ▸Final pathology review: confirm the diagnosis of benign fibroma and review the full report with your gynecologic oncologist.
• ▸Follow-up imaging schedule: a single postoperative ultrasound or CT at six to eight weeks is typical, then as needed.
• ▸Symptom monitoring: report any new abdominal distension, shortness of breath, or weight gain promptly, since these could signal fluid recurrence.
• ▸Fertility and hormonal considerations: younger patients should discuss ovarian preservation, hormone replacement if both ovaries are removed, and family-planning options.

Bottom Line

it is a rare but entirely benign ovarian condition that mimics advanced cancer until pathology proves otherwise. The classic triad of benign fibroma, ascites, and right-sided pleural effusion resolves completely once the tumor is removed, leaving an excellent long-term prognosis.

FAQ